scholarly journals Recent advances in capsule-based dry powder inhaler technology

2017 ◽  
Vol 12 ◽  
Author(s):  
Federico Lavorini ◽  
Massimo Pistolesi ◽  
Omar S. Usmani
Keyword(s):  
Drug Delivery ◽  
Dry Powder Inhaler ◽  
Drug Dosage ◽  
Therapeutic Benefit ◽  
Drug Formulation ◽  
Dry Powder ◽  
Diverse Range ◽  
Recent Advances ◽  
Overall Performance ◽  
Delivery Options

Pulmonary drug delivery is currently the focus of accelerated research and development because of the potential to produce maximum therapeutic benefit to patients by directly targeting drug to the site of pathology in the lungs. Among the available delivery options, the dry powder inhaler (DPI) is the preferred device for the treatment of an increasingly diverse range of diseases. However, because drug delivery from a DPI involves a complex interaction between the device and the patient, the engineering development of this medical technology is proving to be a great challenge. Development of DPI systems that target the delivery of fine drug particles to the deeper airways in the lungs using a combination of improved drug formulations and enhanced delivery device technologies means that each of these factors contributes to overall performance of the aerosol system. There are a large range of devices that are currently available, or under development, for clinical use, however no individual device shows superior clinical efficacy. A major concern that is very relevant in day-to-day clinical practice is the inter- and intra-patient variability of the drug dosage delivered to the deep lungs from the inhalation devices, where the extent of variability depends on the drug formulation, the device design, and the patient’s inhalation profile. This variability may result in under-dosing of drug to the patient and potential loss of pharmacological efficacy. This article reviews recent advances in capsule-based DPI technology and the introduction of the ‘disposable’ DPI device.

scholarly journals Understanding the Importance of Capsules in Dry Powder Inhalers

Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1936
Author(s):  
Francesca Buttini ◽  
Eride Quarta ◽  
Chiara Allegrini ◽  
Federico Lavorini
Keyword(s):  
Dry Powder Inhaler ◽  
Therapeutic Benefit ◽  
Metered Dose Inhalers ◽  
Dry Powder ◽  
Diverse Range ◽  
Inhaler Device ◽  
Metered Dose ◽  
Disease Site ◽  
Drug Reservoir ◽  
Delivery Options

Pulmonary drug delivery is currently the focus of research and development because of its potential to produce maximum therapeutic benefit to patients by directing the drug straight to the lung disease site. Among all the available delivery options, one popular, proven and convenient inhaler device is the capsule-based dry powder inhaler (cDPI) for the treatment of an increasingly diverse range of diseases. cDPIs use a hard capsule that contains a powder formulation which consists of a mixture of a micronized drug and a carrier usually the lactose, known for its good lung tolerance. The capsule is either inserted into the device during manufacturer or by the patient prior to use. After perforating, opening or cut the capsule in the device, patients take a deep and rapid breath to inhale the powder, using air as the vector of drug displacement. The system is simple, relatively cheap and characterized by a lower carbon footprint than that of pressurized metered dose inhalers. This article reviews cDPI technology, focusing particularly on the importance of capsule characteristics and their function as a drug reservoir in cDPIs.

The Effect of Flow Rate on Drug Delivery from the Pulvinal, a High-Resistance Dry Powder Inhaler

1998 ◽  
Vol 11 (3) ◽  
pp. 143-152 ◽  
Author(s):  
B.J. MEAKIN ◽  
D. GANDERTON ◽  
I. PANZA ◽  
P. VENTURA
Keyword(s):  
Drug Delivery ◽  
Flow Rate ◽  
High Resistance ◽  
Dry Powder Inhaler ◽  
Dry Powder

The Impact of Common Inhaler Errors on Drug Delivery: Investigating Critical Errors with a Dry Powder Inhaler

2017 ◽  
Vol 30 (4) ◽  
pp. 247-255 ◽  
Author(s):  
Imran Sulaiman ◽  
Jansen Seheult ◽  
Nirmal Sadasivuni ◽  
Elaine MacHale ◽  
Isabelle Killane ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Dry Powder Inhaler ◽  
Dry Powder ◽  
The Impact

scholarly journals Development of an adaptive bypass element for passive entrainment flow control in dry powder inhalers

2019 ◽  
Vol 233 (15) ◽  
pp. 5201-5213
Author(s):  
Thomas Kopsch ◽  
Darragh Murnane ◽  
Digby Symons
Keyword(s):  
Drug Delivery ◽  
Dry Powder Inhaler ◽  
Experimental Methods ◽  
Dry Powder Inhalers ◽  
Total Flow ◽  
Dry Powder ◽  
Flow Rates ◽  
Inhaler Device ◽  
Flow Resistances ◽  
Flap Valve

The release of drug from dry powder inhalers is strongly dependent on the patient's inhalation profile. To maximise the effect of the treatment, it is necessary to optimise dry powder inhalers to achieve drug delivery that (A) is independent of the inhalation manoeuvre and (B) is targeted to the correct site in the lung. The purpose of this study is to develop a dry powder inhaler with an adaptive bypass element that achieves desired drug delivery behaviour. Computational and experimental methods are used. First, the effect of a generic variable bypass element on entrainment behaviour is modelled. This is done by modelling a dry powder inhaler as a network of flow. Second, the behaviour of a potential variable bypass element, a flap valve, is studied both computationally and experimentally. Third, the flow resistances are optimised to achieve consistent and desired entrainment behaviour for patients with very different inhalation manoeuvres. A simulated dry powder inhaler device design was found that achieves an approximately constant entrainment flow rate of 12 L/min when total flow rates larger than 20 L/min are applied. The developed dry powder inhaler is predicted to accurately deliver drug for patients with highly different inhalation manoeuvres.

Drug Delivery Performance of the Mometasone Furoate Dry Powder Inhaler

2001 ◽  
Vol 14 (4) ◽  
pp. 487-494 ◽  
Author(s):  
T.T. Yang ◽  
S. Li ◽  
B. Wyka ◽  
D. Kenyon
Keyword(s):  
Drug Delivery ◽  
Dry Powder Inhaler ◽  
Mometasone Furoate ◽  
Dry Powder ◽  
Delivery Performance

scholarly journals Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery

Drug Research ◽  
2019 ◽  
Vol 70 (01) ◽  
pp. 26-32
Author(s):  
Fariba Azari ◽  
Saeed Ghanbarzadeh ◽  
Rezvan Safdari ◽  
Shadi Yaqoubi ◽  
Khosro Adibkia ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Spray Drying ◽  
Dry Powder Inhaler ◽  
Ammonium Bicarbonate ◽  
Pulmonary Drug Delivery ◽  
Water Mixture ◽  
Dry Powder ◽  
Scanning Calorimetry ◽  
Aerodynamic Properties ◽  
Systemic Treatments

Abstract Background Pulmonary drug delivery route is gaining much attention because it enables to target the active ingredients directly to lung both for local and systemic treatments, which maximize the therapeutic effect and minimize unwanted systemic toxicity. Dry powder inhaler (DPI) systems for asthma therapy have shown several merits to the other pulmonary delivery systems such as nebulizers and metered dose inhalers. Purpose The present study aims to develop and optimize a DPI formulation for Ketotifen fumarate through spray drying technique. Methods Particles size and morphology, crystallinity, and drug-excipient interaction of fabricated DPI formulations were evaluated by scanning electron microscopy, X-ray diffraction (XRD), differential scanning calorimetry (DSC), and Fourier Transform Infrared Spectroscopy methods, respectively. The aerosolization indexes and aerodynamic properties of dry powders were determined by next generation impactor. The powder flowability was assessed by measuring the Hausner ratio and compressibility index. Results Among solvent systems, ethanol-water mixture produced the most desirable powder property for inhalation after spray drying. Although co-spray dried formulations with ammonium bicarbonate resulted in the porous structure, it was not beneficial for DPI formulations due to the interaction with Ketotifen. DSC and XRD experiments proved the amorphous structure of prepared powders, which were stable for 12 months. Conclusion The results of this study demonstrate the potential of Ketotifen DPI formulation and pave a way to use it easily in an industrial scale.

Sign in / Sign up

Export Citation Format

Share Document